International Journal of Antimicrobial Agents
Volume 36, Issue 3 , Pages 216-221 , September 2010

Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones

Received 13 August 2009 ,Accepted 30 April 2010.

References 

  1. Jevons MP. Celbenin-resistant staphylococci. Br Med J. 1961;1:124–125
  2. Knox R. Celbenin-resistant staphylococci. Br Med J. 1961;1:126
  3. Lacey RW. The mechanism of methicillin resistance. J Antimicrob Chemother. 1986;18:435–439
  4. Berger-Bächi B, Rohrer S. Factors influencing methicillin resistance in staphylococci. Arch Microbiol. 2002;178:165–171
  5. Tomasz A, Nachmann S, Leaf H. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother. 1991;35:124–129
  6. Utsui Y, Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1985;28:397–403
  7. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis. 2005;40:562–573
  8. Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J Antimicrob Chemother. 2005;56:455–462
  9. Marples RR, Reith S. Methicillin-resistant Staphylococcus aureus in England and Wales. Commun Dis Rep CDR Rev. 1992;2:R25–R29
  10. Shanson DC. Antibiotic-resistant Staphylococcus aureus. J Hosp Infect. 1981;2:11–36
  11. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother. 2008;62(Suppl. 1):i1–i9
  12. In:  Reynolds LA,  Tansey EM editor. Superbugs and superdrugs: a history of MRSA. vol. 32:London, UK: Wellcome Trust Centre for the History of Medicine at UCL; 2008;
  13. Johnson AP, Aucken HM, Cavendish S, Ganner M, Wale MC, Warner M, et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother. 2001;48:143–144
  14. Dziekan G, Hahn A, Thüne K, Schwarzer G, Schäfer K, Daschner FD, et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case–control study. J Hosp Infect. 2000;46:263–270
  15. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalised patients. Emerg Infect Dis. 2003;9:1415–1422
  16. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49:999–1005
  17. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36:131–139
  18. Harbarth S, Frankhäuser C, Schrenzel J. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA. 2008;299:1149–1157
  19. Tacconelli E, DeAngelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother. 2008;61:26–38
  20. Dancer SJ. Importance of the environment in methicillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning. Lancet Infect Dis. 2008;8:101–113
  21. Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection. J Hosp Infect. 2009;73:378–385
  22. Crowcroft NS. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol. 1999;20:31–36
  23. Niedersächsisches Landesamt, MRSA-Bedrohung durch Antibiotikatherapie? NLGA aktuell 2004;3:1–2.
  24. Dalhoff A, Schubert S, Ullmann U. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide. Infection. 2005;33(Suppl. 2):36–43
  25. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
  26. Grasso S, Meinardi G, deCarneri I, Tamassia V. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother. 1978;13:570–576
  27. Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother. 1999;43(Suppl. B):51–59
  28. Schubert S, Dalhoff A, Stass H, Ullmann U. Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations. Infection. 2005;33(Suppl. 2):15–21
  29. Dalhoff A, Koeppe P, von Kobyletzki D. Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration. Arzneimittelforschung. 1981;31:1148–1157[in German]
  30. Todd PA, Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990;39:264–307
  31. Dudley MN. Pharmacokinetics of fluoroquinolones. In:  Hooper DC,  Rubinstein E editor. Quinolone antimicrobial agents. 3rd ed.. Washington, DC: ASM Press; 2003;p. 115–132
  32. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999;43(Suppl. B):83–90
  33. Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolones exposure. J Antimcrob Chemother. 2001;48:375–381
  34. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 2003;22:203–221
  35. Thauvin-Eliopoulos C, Eliopoulos GM. Activity in vitro of the quinolones. In:  Hooper DC,  Rubinstein E editor. Quinolone antimicrobial agents. 3rd ed.. Washington, DC: ASM Press; 2003;p. 91–111
  36. Schmitz FJ, Higgins PG, Mayer S, Fluit AC, Dalhoff A. Activity of quinolones against Gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis. 2002;21:647–659
  37. Goldstein EJC, Citron DM, Warren YA, Tyrrell KL, Rybak MJ. Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus. J Med Microbiol. 2008;57:452–456
  38. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy. 1996;42:410–425
  39. Schaper KJ, Schubert S, Dalhoff A. Kinetics and quantification of antibacterial effects of β-lactams, macrolides and quinolones against Gram-positive and Gram-negative RTI pathogens. Infection. 2005;33(Suppl. 2):3–14
  40. Kayser FH, Santanam P, Huf E. Comparative activity of moxifloxacin and other quinolones against staphylococci. Chemother J. 2000;9:114–119[in German]
  41. Graffunder E, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002;49:999–1005
  42. Bisognano C, Vaudaux PE, Lew DP, Ng EYW, Hooper DC. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother. 1997;41:906–913
  43. Bisognano C, Vaudaux P, Rohner P, Lew DP, Hooper DC. Inhibition of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother. 2000;44:1428–1437

PII: S0924-8579(10)00233-5

doi: 10.1016/j.ijantimicag.2010.04.014

International Journal of Antimicrobial Agents
Volume 36, Issue 3 , Pages 216-221 , September 2010

Article Tools

* Image Usage & Resolution